4.0 Article Proceedings Paper

The DDAH/ADMA/NOS pathway

Journal

ATHEROSCLEROSIS SUPPLEMENTS
Volume 4, Issue 4, Pages 33-40

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/S1567-5688(03)00032-1

Keywords

asymmetric dimethylarginine; nitric oxide; dimethylarginine dimethylaminohydrolase; cardiovascular disease

Ask authors/readers for more resources

An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS), particularly asymmetric dimethylarginine (ADMA) regulate nitric oxide generation in numerous disease states. Two dimethylarginine dimethylaminobydrolase (DDAH) enzymes metabolise ADMA. We and others have postulated that activity of DDAH is a key determinant of ADMA levels in vivo. This review summarises recent advances in the regulation and function of DDAH enzymes and its role in the regulation of nitric oxide generation. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available